Translational findings for odronextamab: From preclinical research to a first‐in‐human study in patients with CD20+ B‐cell malignancies

• Main Authors: Min Zhu (Author), Kara Olson (Author), Jessica R. Kirshner (Author), Masood Khaksar Toroghi (Author), Hong Yan (Author), Lauric Haber (Author), Craig Meagher (Author), Dina M. Flink (Author), Srikanth R. Ambati (Author), John D. Davis (Author), A. Thomas DiCioccio (Author), Eric J. Smith (Author), Marc W. Retter (Author)
• Format: Book
• Published: Wiley, 2022-04-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Odronextamab is a fully‐human IgG4‐based CD20xCD3 bispecific antibody that binds to CD3 on T cells and CD20 on B cells, triggering T‐cell‐mediated cytotoxicity independent of T‐cell‐receptor recognition. Adequate safety, tolerability, and encouraging durable complete responses have been obs...